Two companies expressed intent to get EUA for the Sinopharm COVID-19 vaccine, according to FDA.
The Food and Drug Administration (FDA) said that two companies expressed intent to get EUA for the Sinopharm COVID-19 vaccine.
In a press briefing, FDA Director-General Eric Domingo said that the Food and Drug Administration had received two letters from two different firms expressing intent to apply for emergency use authorization (EUA) of the COVID-19 vaccine developed by China’s Sinopharm Group.
According to Domingo, the FDA had responded to both letters, informing them of the requirements and the process of EUA application.
However, Domingo said that neither of these firms have responded, adding that there’s still no officially filed EUA application with documents and requirements with the FDA when it comes to Sinopharm as of now.
READ ALSO | Palace: President Duterte To Wait For Sinopharm To Secure EUA
“I don’t know if it’s in behalf of Sinopharm. There are two companies [that] wrote us with a letter of intent to apply for an EUA for the product Sinopharm vaccine. But neither of them have responded, so as of now, there is still no officially filed application with documents and requirements with the FDA when it comes to Sinopharm,” Domingo said.
Earlier, Domingo said that one company filed an online EUA application for the Sinopharm COVID-19 vaccine but later clarified that the applicant had not yet submitted the required documents.
Meanwhile, the Food and Drug Administration approved the emergency use of Russia’s Sputnik V COVID-19 vaccine in the Philippines.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.
